title: Right Ventricular Dysfunction Complicates Time in Therapeutic Range in Heart Failure Patients Receiving Warfarin.
abstract: OBJECTIVE
  We aimed to evaluate the effect of echocardiographically demonstrated right ventricular dysfunction (RVD) on time in therapeutic range (TTR) in heart failure (HF) patients receiving warfarin therapy.
  
  
  METHODS
  A total of 893 consecutive HF patients were included and classified into 4 different subgroups: HF with preserved ejection fraction (HFpEF) without RVD (n = 373), HF with reduced EF (HFrEF) without RVD (n = 215), HFpEF with RVD (n = 106) and HFrEF with RVD (n = 199). Groups were compared according to baseline, demographic and clinical data and the characteristics of warfarin therapy.
  
  
  RESULTS
  Presence of RVD yielded lower median TTR values both in HFpEF and HFrEF patients. RVD, current smoking, New York Heart Association functional class III/IV, hypertension, diabetes mellitus, pulmonary disease, prior transient ischemic attack or stroke, chronic kidney disease (CKD) stage 4/5 and CKD stage 3 were found to be independent predictors of poor anticoagulation control in multivariate logistic regression analysis.
  
  
  CONCLUSIONS
  The present study demonstrated that presence of RVD in HF increases the risk for poor anticoagulation.
authors.affiliation: Department of Cardiology, Heart Center, University Hospital, Cumhuriyet University, Sivas, Turkey.
authors.forename: Osman
authors.initials: O
authors.lastname: Beton
authors.forename: Lale Dinc
authors.initials: LD
authors.lastname: Asarcikli
authors.forename: Taner
authors.initials: T
authors.lastname: Sen
authors.forename: Esra Gucuk
authors.initials: EG
authors.lastname: Ipek
authors.forename: Habibe
authors.initials: H
authors.lastname: Kafes
authors.forename: Mehmet
authors.initials: M
authors.lastname: Yaman
authors.forename: Tolga Han
authors.initials: TH
authors.lastname: Efe
authors.forename: Hakkı
authors.initials: H
authors.lastname: Kaya
authors.forename: Ahmet
authors.initials: A
authors.lastname: Temizhan
authors.forename: Mehmet Birhan
authors.initials: MB
authors.lastname: Yilmaz
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005260:Female; D006333:Heart Failure / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D018497:Ventricular Dysfunction, Right / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000503:physiopathology; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D014859:Warfarin